Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7505012rdf:typepubmed:Citationlld:pubmed
pubmed-article:7505012lifeskim:mentionsumls-concept:C0024264lld:lifeskim
pubmed-article:7505012lifeskim:mentionsumls-concept:C0010853lld:lifeskim
pubmed-article:7505012lifeskim:mentionsumls-concept:C0243982lld:lifeskim
pubmed-article:7505012lifeskim:mentionsumls-concept:C0597357lld:lifeskim
pubmed-article:7505012lifeskim:mentionsumls-concept:C1332712lld:lifeskim
pubmed-article:7505012lifeskim:mentionsumls-concept:C0037083lld:lifeskim
pubmed-article:7505012lifeskim:mentionsumls-concept:C1704675lld:lifeskim
pubmed-article:7505012pubmed:issue12lld:pubmed
pubmed-article:7505012pubmed:dateCreated1994-1-14lld:pubmed
pubmed-article:7505012pubmed:abstractTextThe purposes of this study are to characterize the binding of hyaluronic acid (HA) to mouse T lymphoma cells, to measure changes in intracellular Ca2+ after HA binding, to elucidate the interaction between the HA receptor, GP85(CD44), and ankyrin in the membrane skeleton, and finally to correlate these events with HA receptor patching/capping and cell adhesion to HA. First, we established an in vivo assay using [3H]HA to measure the binding of HA to mouse T lymphoma cells, and found that the binding of [3H]HA to these cells is readily inhibited by the addition of anti-GP85(CD44) antibody suggesting that GP85(CD44) is the HA receptor. Next, we examined various signal transducing events that occur after HA binds to its receptor on mouse T lymphoma cells. The results of these studies indicate that the concentration of intracellular Ca2+ (as measured by Fura-2 fluorescence) begins to increase within seconds, and reaches a maximal level 5 min after the addition of HA to the cells. After this increase of intracellular Ca2+, HA induces both its receptors, GP85(CD44), to form patched/capped structures, and cell adhesion to HA-coated plates. Furthermore, we have determined that GP85(CD44) binds directly and specifically to ankyrin (Kd approximately 1.94 nM) in a saturable manner; and that ankyrin is preferentially accumulated underneath the HA-induced GP85(CD44) capped structures. The Ca2+ ionophore, ionomycin, was found to stimulate HA-induced receptor capping and adhesion while EGTA (a Ca2+ chelator), nefedipine/bepridil (Ca2+ channel blockers), W-7 (a calmodulin antagonist), and cytochalasin D (a microfilament inhibitor), but not colchicine (a microtubule disrupting agent), inhibit HA-induced receptor redistribution and adhesion to HA-coated plates. These findings strongly suggest that ankyrin plays an important role in linking the HA receptor, GP85(CD44), to the membrane-associated actomyosin contractile system during hyaluronic acid-mediated lymphocyte activation.lld:pubmed
pubmed-article:7505012pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7505012pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7505012pubmed:languageenglld:pubmed
pubmed-article:7505012pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7505012pubmed:citationSubsetAIMlld:pubmed
pubmed-article:7505012pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7505012pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7505012pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7505012pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7505012pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7505012pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7505012pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7505012pubmed:statusMEDLINElld:pubmed
pubmed-article:7505012pubmed:monthDeclld:pubmed
pubmed-article:7505012pubmed:issn0022-1767lld:pubmed
pubmed-article:7505012pubmed:authorpubmed-author:KerrickW GWGlld:pubmed
pubmed-article:7505012pubmed:authorpubmed-author:BourguignonL...lld:pubmed
pubmed-article:7505012pubmed:authorpubmed-author:ChewAAlld:pubmed
pubmed-article:7505012pubmed:authorpubmed-author:LokeshwarV...lld:pubmed
pubmed-article:7505012pubmed:issnTypePrintlld:pubmed
pubmed-article:7505012pubmed:day15lld:pubmed
pubmed-article:7505012pubmed:volume151lld:pubmed
pubmed-article:7505012pubmed:ownerNLMlld:pubmed
pubmed-article:7505012pubmed:authorsCompleteYlld:pubmed
pubmed-article:7505012pubmed:pagination6634-44lld:pubmed
pubmed-article:7505012pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:7505012pubmed:meshHeadingpubmed-meshheading:7505012-...lld:pubmed
pubmed-article:7505012pubmed:meshHeadingpubmed-meshheading:7505012-...lld:pubmed
pubmed-article:7505012pubmed:meshHeadingpubmed-meshheading:7505012-...lld:pubmed
pubmed-article:7505012pubmed:meshHeadingpubmed-meshheading:7505012-...lld:pubmed
pubmed-article:7505012pubmed:meshHeadingpubmed-meshheading:7505012-...lld:pubmed
pubmed-article:7505012pubmed:meshHeadingpubmed-meshheading:7505012-...lld:pubmed
pubmed-article:7505012pubmed:meshHeadingpubmed-meshheading:7505012-...lld:pubmed
pubmed-article:7505012pubmed:meshHeadingpubmed-meshheading:7505012-...lld:pubmed
pubmed-article:7505012pubmed:meshHeadingpubmed-meshheading:7505012-...lld:pubmed
pubmed-article:7505012pubmed:meshHeadingpubmed-meshheading:7505012-...lld:pubmed
pubmed-article:7505012pubmed:meshHeadingpubmed-meshheading:7505012-...lld:pubmed
pubmed-article:7505012pubmed:meshHeadingpubmed-meshheading:7505012-...lld:pubmed
pubmed-article:7505012pubmed:meshHeadingpubmed-meshheading:7505012-...lld:pubmed
pubmed-article:7505012pubmed:meshHeadingpubmed-meshheading:7505012-...lld:pubmed
pubmed-article:7505012pubmed:meshHeadingpubmed-meshheading:7505012-...lld:pubmed
pubmed-article:7505012pubmed:meshHeadingpubmed-meshheading:7505012-...lld:pubmed
pubmed-article:7505012pubmed:year1993lld:pubmed
pubmed-article:7505012pubmed:articleTitleHyaluronic acid-induced lymphocyte signal transduction and HA receptor (GP85/CD44)-cytoskeleton interaction.lld:pubmed
pubmed-article:7505012pubmed:affiliationDepartment of Cell Biology and Anatomy, University of Miami Medical School, FL 33101.lld:pubmed
pubmed-article:7505012pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7505012pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:7505012pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:960entrezgene:pubmedpubmed-article:7505012lld:entrezgene
entrez-gene:286entrezgene:pubmedpubmed-article:7505012lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:7505012lld:entrezgene
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7505012lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7505012lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7505012lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7505012lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7505012lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7505012lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7505012lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7505012lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7505012lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7505012lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7505012lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7505012lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7505012lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7505012lld:pubmed